Supernus Pharmaceuticals, Inc. Stock News

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Peter Vozzo - Investor Relations-ICR Healthcare Jack Khattar - Chief Executive Officer Tim Dec - Chief Financial Officer Conference Call Participants Stacy Ku - TD Cowen David Amsellem - Piper Sandler Operator Good afternoon and welcome to Supernus Pharmaceuticals First Qua...

First quarter 2025 net sales of Qelbree® increased 44% to $64.7 million, compared to the same period in 2024. First quarter 2025 net sales of GOCOVRI® increased 16% to $30.7 million, compared to the same period in 2024.

ROCKVILLE, Md., April 23, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the first quarter of 2025 after the market closes on Tuesday, May 6, 2025.

ROCKVILLE, Md., March 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in the following March investor conferences:

ROCKVILLE, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the TD Cowen 45th Annual Health Care ...

Supernus Pharmaceuticals, Inc. (SUPN) Q4 2024 Earnings Call Transcript

ROCKVILLE, Md., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for fourth quarter and full year 2024 and associated Company developments.

BOSTON, MA / ACCESS Newswire / February 24, 2025 / Block & Leviton is investigating Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN) for potential securities law violations. Investors who have lost money in their Supernus Pharmaceuticals, Inc. investment should contact the firm to learn more about how they might recover those losses.